Since 2020, Hanna Glasebach has been a research associate in the Innovation Field Cell and Tissue Technologies at Fraunhofer IGB. She studied biochemistry at the Eberhard Karls University of Tübingen and has been working on the establishment of a 3D in-vitro skin model for the validation of new targets for the treatment of psoriasis since then.
Professional career |
|
| Since 2020 | Research associate in the Innovation Field Cell and Tissue Technologies at Fraunhofer IGB |
| 2018 – 2020 | M. Sc. (Biochemistry) at Eberhard Karls University, Tübingen |
| 2014 – 2018 | B. Sc. (Biochemistry) at Eberhard Karls University, Tübingen |
| 2016 – 2017 | Study abroad at Capital Normal University and Tsinghua University, Beijing, China |
| Project title | Project title long | Funding source | Period |
| ImmuDarm | human organ models for testing products against chronic inflammatory bowel disease | Fraunhofer | January 2022 – December 2024 |
| Psoriceptors | Validation of innate immune receptors as targets for the treatment of psoriasis | BMBF | May 2020 – April 2022 |
| Immunsystem-to-go | Toll-like receptor assays – a new technology platform for Next Generation Immunoassays | BMBF | July 2019 – June 2022 |
| DAAD scholarship |
| YEAR | TITLE/AUTHOR |
| 2020 | Hans, F., Glasebach, H., & Kahle, P. J. (2020). Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. The Journal of biological chemistry, 295(3), 673–689. https://doi.org/10.1074/jbc.RA119.010617 |
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB